Description

Cartalax 20mg Bioregulator – Ala-Glu-Asp (AED) Research Peptide

Cartalax 20mg Bioregulator is a synthetic tripeptide associated with scientific investigations into cellular regulation, tissue biology, gene expression and experimental ageing-related processes. Also known as the AED peptide or T-31, Cartalax contains three amino acids: alanine, glutamic acid and aspartic acid.

Cartalax belongs to the family of short synthetic peptides associated with the research of Vladimir Khavinson and colleagues. These compounds have been investigated as experimental models for understanding how short amino acid sequences may influence cellular behaviour.

Although Cartalax is frequently described as a cartilage-associated bioregulator, its published scientific literature includes investigations involving skin fibroblasts, kidney tissue cultures and mesenchymal stem cells. Direct evidence supporting cartilage repair in humans remains insufficient.

The Cartalax 20mg product is therefore relevant to laboratory research involving peptide structure, cellular ageing, tissue-associated signalling and short-peptide biochemistry.

What Is Cartalax Peptide?

Cartalax is a synthetic peptide containing three amino acid residues.

Its sequence is Ala-Glu-Asp, abbreviated AED using the standard one-letter amino acid code.

The peptide has also appeared in scientific literature under the experimental designation T-31.

Cartalax is associated with the Khavinson short-peptide research programme, which investigated a range of small peptides for possible tissue-associated biological activity.

The term bioregulator refers to a proposed ability to influence biological processes. It does not mean that Cartalax has been clinically proven to regulate cartilage regeneration or treat human disease.

Cartalax 20mg Product Specifications

• Product Name: Cartalax 20mg Bioregulator
• Alternative Names: Cartalax, AED peptide, T-31 peptide
• Peptide Classification: Synthetic short-peptide bioregulator
• Peptide Type: Tripeptide
• Reference Sequence: Ala-Glu-Asp
• One-Letter Sequence: AED
• Peptide Length: 3 amino acid residues
• Reference Molecular Formula: C12H19N3O8
• Approximate Molecular Weight: 333.29 g/mol
• Reference Structure: H-Ala-Glu-Asp-OH
• PubChem Compound ID: 87815447
• Labelled Quantity: 20mg
• Research Category: Short-peptide bioregulator research
• Research Focus: Cellular ageing, tissue biology and gene expression
• Purity: Requires batch-specific verification
• Salt Form: Confirm with manufacturer
• Physical Form: Confirm with manufacturer
• Storage: Follow verified manufacturer instructions
• Intended Use: Laboratory research only

The reference molecular formula and molecular weight describe the free-acid AED tripeptide. Commercial preparations may contain counterions, water or other components that influence the measured material composition.

Understanding the Molecular Structure of Cartalax

Cartalax contains three amino acid residues connected by peptide bonds.

The sequence consists of:

• Alanine (Ala): A small amino acid with a methyl-containing side chain.
• Glutamic Acid (Glu): An acidic amino acid containing a carboxyl-bearing side chain.
• Aspartic Acid (Asp): An acidic amino acid with a shorter carboxyl-bearing side chain.

The peptide’s small molecular size makes it relevant to investigations into short-peptide chemistry and biological interactions.

Cartalax should not be confused with related peptides that contain additional amino acid residues.

For example, Epitalon contains the sequence Ala-Glu-Asp-Gly, while Cardiogen contains Ala-Glu-Asp-Arg.

These molecules share part of their amino acid sequences but have distinct chemical identities.

How Does Cartalax Work?

Cartalax has been investigated within a broader research programme exploring how short synthetic peptides may influence cellular activity.

Some studies involving the AED sequence have reported changes in selected cellular markers, gene expression patterns and tissue-culture responses.

Researchers have proposed that certain short peptides may interact with intracellular regulatory mechanisms.

However, a specific, independently established molecular receptor or clinically validated mechanism of action for Cartalax has not been identified.

The proposed biological effects remain primarily based on experimental laboratory findings.

Results obtained in cultured cells cannot establish that Cartalax repairs cartilage, reverses ageing or improves health outcomes in humans.

Scientific Research Into Cartalax

1. Cartilage and Connective Tissue Research

Cartalax is frequently associated with cartilage biology because of its historical classification within the short-peptide bioregulator family.

Cartilage is a specialised connective tissue containing chondrocytes and an extracellular matrix rich in collagen and proteoglycans.

Healthy cartilage contributes to joint function and mechanical support.

Although Cartalax has been proposed as a cartilage-associated research peptide, the available evidence supporting direct cartilage regeneration is limited.

Some published and regional experimental reports have explored cartilage-related cellular markers, but these findings require independent confirmation.

There is no established clinical evidence that Cartalax regenerates damaged human cartilage or treats osteoarthritis.

2. Cellular Ageing Research

Cellular ageing involves changes in gene expression, metabolism, stress responses and tissue maintenance.

Researchers have investigated short synthetic peptides as experimental tools for examining ageing-associated cellular processes.

Cartalax has appeared in studies evaluating cellular responses in ageing-related laboratory models.

Some investigations reported changes in selected markers associated with cellular function.

However, these observations do not demonstrate that Cartalax reverses biological ageing or extends human lifespan.

3. Skin Fibroblast Research

Fibroblasts are connective tissue cells involved in the production and maintenance of extracellular matrix components.

They contribute to the structural organisation of skin and other connective tissues.

Research involving the AED peptide has examined fibroblast functions during experimental cellular ageing.

Published laboratory findings have reported changes in selected fibroblast-related responses.

These studies contribute to understanding short-peptide interactions with connective tissue cells.

They do not establish Cartalax as an effective anti-ageing skin treatment.

4. Kidney Tissue Culture Research

Cartalax has also been investigated in experimental kidney tissue cultures.

Kidney cells perform specialised functions involved in filtration, transport and physiological regulation.

A 2015 study examined short-peptide effects on cellular renewal processes in kidney tissue cultures derived from young and old animals.

The AED peptide was included in this research under the designation T-31.

These findings are relevant to basic tissue biology but do not establish kidney protection or therapeutic benefits in humans.

5. Mesenchymal Stem Cell Research

Mesenchymal stem cells are multipotent cells investigated in tissue biology and regenerative medicine research.

They can differentiate into several cell types under appropriate experimental conditions.

Studies involving short peptide bioregulators have examined gene expression in ageing mesenchymal stem cell cultures.

Cartalax has been included in investigations of peptide-associated changes in cellular markers.

However, changes in stem cell gene expression do not establish successful tissue regeneration in living humans.

6. Gene Expression Research

Gene expression is the process through which information encoded in DNA contributes to the production of RNA and proteins.

Short synthetic peptides have been investigated for their possible interactions with cellular regulatory pathways.

Some studies associated with the Khavinson research programme have reported changes in gene expression following exposure to selected peptide sequences.

Cartalax is relevant to this research because it contains the AED tripeptide sequence.

However, the molecular mechanisms underlying these observations remain incompletely established.

Independent replication is necessary before broad conclusions can be drawn.

7. Peptide Bioregulator Research

The peptide bioregulator concept describes a research approach involving short amino acid sequences and their possible influence on cellular processes.

Cartalax is one of several compounds associated with this programme.

Other examples include Epitalon, Cardiogen, Bronchogen and Cortagen.

These peptides differ in sequence length and amino acid composition.

Research involving one bioregulator does not automatically establish the biological effects of another.

8. Extracellular Matrix Research

The extracellular matrix is a network of proteins and other molecules that provides structural support to cells and tissues.

Collagen, proteoglycans and additional matrix components contribute to connective tissue function.

Because Cartalax has been investigated in connective tissue-associated laboratory models, it is relevant to broader discussions of extracellular matrix biology.

However, direct evidence that Cartalax reliably increases collagen production or restores damaged human cartilage remains insufficient.

9. Short-Peptide Structure-Activity Research

Structure-activity relationship research examines how molecular structure influences biological properties.

Cartalax provides a simple three-residue peptide model for studying sequence-dependent chemical and cellular interactions.

Its AED sequence can be compared with related tetrapeptides that contain an additional amino acid.

Such comparisons may help researchers investigate how small structural changes affect molecular behaviour.

However, shared amino acid sequences do not establish identical biological activity.

Cartalax vs Epitalon

Cartalax and Epitalon are related short synthetic peptides, but they are not the same molecule.

• Cartalax: Ala-Glu-Asp (AED), containing three amino acid residues.
• Epitalon: Ala-Glu-Asp-Gly (AEDG), containing four amino acid residues.
• Molecular Structure: Epitalon contains an additional glycine residue.
• Research Focus: Both appear in short-peptide research literature, but their experimental findings must be evaluated separately.

Research involving Epitalon and telomerase-related processes should not automatically be attributed to Cartalax.

Cartalax vs Bronchogen

Cartalax and Bronchogen are chemically distinct peptides.

Cartalax is the tripeptide Ala-Glu-Asp.

Bronchogen is associated with the tetrapeptide Ala-Glu-Asp-Leu.

The additional leucine residue changes the molecular structure.

Researchers should verify the complete sequence of the supplied material because commercial descriptions sometimes confuse these compounds.

Cartalax vs Cardiogen

Cardiogen is another short synthetic peptide associated with the Khavinson research programme.

Its sequence is Ala-Glu-Asp-Arg, abbreviated AEDR.

Cartalax contains only the Ala-Glu-Asp sequence.

Although the peptides share the same first three amino acids, their chemical identities differ.

Research findings involving Cardiogen cannot establish the effects of Cartalax.

Cartalax and Joint Research

Cartalax is frequently discussed in connection with joints and cartilage because of its classification as a cartilage-associated peptide bioregulator.

Joint function depends on cartilage, bone, ligaments, tendons and surrounding tissues.

Cartilage degeneration is involved in several joint disorders, including osteoarthritis.

However, there is insufficient reliable clinical evidence that Cartalax restores cartilage thickness, improves joint mobility or relieves osteoarthritis symptoms.

It should not be described as a clinically proven joint-repair treatment.

Cartalax and Anti-Ageing Research

Cartalax has been investigated in experimental models involving cellular ageing.

Some studies reported changes in selected markers associated with cellular renewal or gene expression.

However, these findings do not demonstrate that Cartalax reverses human ageing or extends lifespan.

Its long-term safety and clinical effectiveness remain unestablished.

Cartalax and Weight Management

Cartalax is not an established weight-loss peptide.

Its primary research associations involve short-peptide biochemistry, cellular regulation and experimental tissue biology.

There is insufficient reliable clinical evidence that Cartalax reduces body fat, suppresses appetite or treats obesity.

It should not be described as a proven fat-burning or metabolic weight-management compound.

Understanding the Cartalax 20mg Label

The 20mg designation refers to the labelled quantity of research material.

It does not represent a recommended human dose or independently establish purity, identity or biological activity.

Researchers should verify whether the stated mass refers to the free peptide or includes counterions and other formulation components.

Batch-specific analytical documentation is necessary to establish the actual characteristics of the supplied material.

Cartalax 20mg Research Quality and Documentation

Important considerations when evaluating Cartalax research material include:

• Verification of the complete Ala-Glu-Asp sequence
• Confirmation that the peptide contains three amino acid residues
• Distinction from AEDL, AEDG and AEDR peptides
• Verification of the supplied molecular form
• Identification of the peptide salt form
• Batch-specific certificate of analysis
• Appropriate analytical purity testing
• Mass spectrometry or another suitable identity method
• Confirmation of the labelled 20mg quantity
• Assessment of synthesis-related impurities
• Manufacturer and batch traceability
• Documentation of counterions and formulation components
• Verified packaging specifications
• Product-specific storage and stability information
• Clearly stated research-use classification

These records help distinguish accurately characterised Cartalax from incorrectly labelled peptide products.

Storage and Handling of Cartalax

Cartalax research material should be stored according to verified manufacturer instructions.

Storage requirements depend on the peptide’s salt form, physical presentation, formulation and packaging.

Researchers should not assume that all Cartalax products have identical stability or shelf-life characteristics.

Laboratory handling should follow relevant safety documentation and institutional procedures.

Cartalax Safety and Scientific Limitations

Cartalax is an investigational peptide with no established human clinical safety profile.

Available research primarily involves laboratory models and selected preclinical investigations.

Potential concerns include peptide-related impurities, formulation-dependent reactions, unknown biological effects and insufficient long-term safety information.

Cartalax is not an established approved medicine for cartilage repair, osteoarthritis, ageing or weight management.

Research-grade material should not be assumed suitable for human administration.

This information is intended for scientific and educational purposes only and does not provide medical advice, human dosing recommendations or administration instructions.

Frequently Asked Questions About Cartalax 20mg

What is Cartalax 20mg?

Cartalax 20mg is a product listing for the synthetic AED tripeptide with a labelled quantity of 20mg.

What is the Cartalax peptide sequence?

The reference sequence is Ala-Glu-Asp, abbreviated AED.

How many amino acids are in Cartalax?

Cartalax contains three amino acid residues.

What is the molecular weight of Cartalax?

The reference free-acid peptide has an approximate molecular weight of 333.29 g/mol.

What is another name for Cartalax?

Cartalax is also referred to as the AED peptide or T-31 peptide.

Is Cartalax the same as Epitalon?

No. Cartalax is AED, while Epitalon is AEDG.

Is Cartalax the same as Bronchogen?

No. Cartalax is the AED tripeptide, while Bronchogen is associated with the AEDL tetrapeptide.

What is Cartalax researched for?

Cartalax has been investigated in cellular ageing, fibroblast biology, kidney tissue cultures and gene expression research.

Does Cartalax regenerate cartilage?

There is insufficient reliable clinical evidence establishing cartilage regeneration in humans.

Is Cartalax a treatment for osteoarthritis?

No. Cartalax is not an established approved treatment for osteoarthritis.

Is Cartalax a weight-loss peptide?

No. It is not an established treatment for obesity or weight management.

What does the 20mg designation mean?

It refers to the labelled quantity of research material, not a recommended human dose.

Cartalax 20mg – Product Summary

Cartalax 20mg Bioregulator is a synthetic tripeptide containing the amino acid sequence Ala-Glu-Asp.

Also known as AED or T-31, it belongs to the Khavinson short-peptide research family and has been investigated in laboratory studies involving cellular ageing, tissue biology and gene expression.

Although Cartalax is commonly associated with cartilage research, direct human clinical evidence supporting cartilage repair or osteoarthritis treatment remains insufficient.

Researchers should verify the complete peptide sequence, molecular identity, purity, salt form, labelled quantity and batch-specific documentation before selecting Cartalax 20mg for laboratory investigation.